Clinical importance of the Step 3 choice in asthma [3]

Thorax

Volumn 61, Issue 2, 2006, Pages 180-181

  Barnes, M L ^a   Lipworth, B J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LONG ACTING DRUG;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; DISEASE EXACERBATION; HUMAN; INFLAMMATION; LETTER; LUNG CLEARANCE; PRIORITY JOURNAL; SMOOTH MUSCLE; SYMPTOMATOLOGY;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ASTHMA; HARM REDUCTION; HUMANS; RANDOMIZED CONTROLLED TRIALS;

EID: 32544452122     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2005.055632     Document Type: Letter

References (3)

1. Masoli M, Weatherall M, Holt S, et al. Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma. Thorax 2005;60:730-4.
2. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 2000;320:1368-73.
3. Currie GP, Bates CE, Lee DK, et al. Effects of fluticasone plus salmeterol versus twice the dose of fluticasone in asthmatic patients. Eur J Clin Pharmacol 2003;59:11-5.